Exicure (XCUR) said its subsidiary, GPCR Therapeutics USA, dosed the 19th patient in an ongoing phase 2 clinical trial of a small molecule inhibitor in multiple myeloma patients undergoing autologous stem cell transplant.
The trial is expected to finish patient recruitment at the end of April.
The study is a multi-center trial evaluating the safety and efficacy of the CXCR4 inhibitor, GPC-100 (burixafor), and propranolol in combination with G-CSF, the company said late Monday.
It said the study's preliminary results are encouraging as 100% of patients achieved the primary endpoint of successful stem cell mobilization.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。